Solid-organ transplantation has advanced through powerful immunosuppression, better diagnostics, and novel biologics. Acute rejection is now uncommon, but chronic graft loss and the toxicity of lifelong immunosuppression remain the central challenges — and the field has just entered two genuinely new eras: costimulation blockade and clinical xenotransplantation.
Maintenance immunosuppression and its alternatives
The standard regimen — a calcineurin inhibitor (tacrolimus), mycophenolic acid, and tapered corticosteroids — keeps acute rejection low but carries chronic nephrotoxicity, infection, malignancy, and metabolic costs. Belatacept, which blocks CD80/86 costimulation, offers a calcineurin-free option that preserves renal function, though at the cost of more early acute rejection and a risk of post-transplant lymphoproliferative disease in EBV-seronegative recipients. mTOR inhibitors (sirolimus, everolimus) enable calcineurin minimization and reduce viral infection and skin cancer, but bring their own tolerability issues. For antibody-mediated rejection, eculizumab (complement blockade) and IL-6-pathway agents (clazakizumab, tocilizumab) are used in sensitized or chronic cases.
Costimulation blockade: tegoprubart
The emerging agent to watch is tegoprubart, an anti-CD40L (CD40 ligand) antibody that interrupts a key costimulatory pathway. It is being evaluated as a calcineurin-free maintenance therapy in conventional kidney transplantation and has performed well enough on early efficacy and safety to advance in trials — and, strikingly, it has become a cornerstone of the immunosuppression used in the first pig-kidney xenotransplants.
Xenotransplantation: from concept to clinic
The most historic development is the arrival of gene-edited pig kidney xenotransplantation in living humans. Beginning with the first such transplant in early 2024 and reported in the medical literature in 2025, a small number of patients with end-stage kidney disease have now received kidneys from pigs carrying dozens of genomic edits (removing xenoantigens and adding human regulatory genes), supported by novel immunosuppression including tegoprubart. Early recipients have had grafts function for weeks to months, formal clinical trials are now launching, and while immune, infectious, and durability hurdles remain, xenotransplantation has moved from theory toward a potential answer to the organ shortage.
Monitoring
Molecular diagnostics — donor-derived cell-free DNA and gene-expression profiling — increasingly allow earlier, less invasive detection of subclinical or acute rejection, complementing therapeutic drug monitoring.
| Agent/approach | Role | Key point |
|---|---|---|
| CNI + MPA + steroids | Maintenance | Standard; chronic toxicity |
| Belatacept | CNI-free maintenance | Renal protection; PTLD risk in EBV-negative |
| mTOR inhibitors | CNI minimization | Lower viral/skin cancer; tolerability issues |
| Eculizumab / IL-6 agents | Antibody-mediated rejection | Sensitized / chronic AMR |
| Tegoprubart (anti-CD40L) | Emerging maintenance; xenotransplant | Costimulation blockade |
| Pig kidney xenotransplant | End-stage disease | Now in first human recipients / trials |
Further reading: porcine kidney xenotransplantation (Kawai et al., NEJM 2025); tegoprubart in kidney transplantation (Phase 2 trials); reviews of maintenance immunosuppression and antibody-mediated rejection (2023–2025).